KOSDAQBiotech & Pharma145020

Hugel

₩180,500▼ 0.06%2026-10-02 close

Market Cap

₩2.3T

Turnover

₩7.1B

Volume

40,000 shares

Shares out.

12.5M

PER

16.6×

PBR

2.5×

EPS

₩14,669

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

US Direct-Sales Pivot: Weighing Growth Against Margin

Hugel has set record quarterly revenue as it shifts its botulinum toxin Letybo to direct sales in the United States, but the cost of building that organization has pulled its operating margin down into the 40 percent range, marking a transition phase.

1
Second-quarter 2026 revenue reached 137.9 billion won, a quarterly record, while operating profit of 56.0 billion won was slightly below the 56.7 billion won of a year earlier, taking the operating margin into the 40 percent range.
2
The company attributed the capped profit growth to upfront spending on the US direct-sales build-out and marketing; second-quarter selling and administrative expenses were reported at 49.7 billion won, up 66 percent year on year.
3
Direct sales began on July 8, 2026 in Los Angeles, moving the US business to a hybrid model that runs partner distribution and direct selling in parallel.
4
First-half 2026 toxin revenue rose 46.6 percent year on year to 149.4 billion won, and overseas toxin and filler sales of 162.1 billion won accounted for roughly 64 percent of total revenue.
5
Domestic toxin and filler sales combined, however, grew just 2.5 percent to 53.5 billion won in the first half, underlining a growth profile heavily dependent on overseas markets.

Business structure

Founded in 2001 and listed on KOSDAQ in 2015, Hugel is a medical aesthetics company whose core business is the development, manufacturing and sale of type A botulinum toxin and hyaluronic acid fillers under brands such as Botulax, The Chaeum and Wellage.

Botulax is sold overseas under the Letybo brand, and the company is described as the first Korean firm to have entered all three major toxin markets: the United States, China and Europe.

By product, first-half 2026 sales were reported at 149.4 billion won for toxin, 66.1 billion won for filler and skin boosters, and 39.0 billion won for cosmetics and other lines.

Geographically, the second-quarter 2026 revenue split was reported as 33 percent domestic and 67 percent overseas, while the export share of products per company filings rose from 53.3 percent in 2023 to 58.6 percent in 2024 and 63.2 percent in 2025.

In the United States, following FDA approval in February 2024, the product launched in March 2025 through distributor BENEV, and from July 2026 the company runs its own direct sales alongside that channel.

In China, it received National Medical Products Administration approval in 2020 as the first Korean company to do so and continues distribution and medical education work with a local partner.

More recently it began selling an extracellular matrix based skin booster from Hans Biomed, broadening the treatment portfolio beyond toxin and filler.

On ownership, Aphrodite Acquisition Holdings and related parties, a consortium including GS Group, CBC Group, Mubadala and IMM Investment, held 45.58 percent as of August 4, 2026.

Earnings trend

Quarterly revenue · Operating profit

₩110.3B₩56.7B25Q2₩105.9B₩47.4B25Q3₩119.1B₩57.8B25Q4₩116.6B₩47.6B26Q1₩137.9B₩56B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩281.7B₩101.4B2022₩319.7B₩117.8B2023₩373B₩166.2B2024₩425.1B₩200.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩110.3B	₩56.7B	51.4%
2025Q3	₩105.9B	₩47.4B	44.8%
2025Q4	₩119.1B	₩57.8B	48.5%
2026Q1	₩116.6B	₩47.6B	40.8%
2026Q2	₩137.9B	₩56B	40.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩281.7B	₩101.4B	₩57.3B	36.0%	7.2%	23.6%
2023	₩319.7B	₩117.8B	₩93.1B	36.8%	12.5%	19.2%
2024	₩373B	₩166.2B	₩135.8B	44.6%	16.9%	11.7%
2025	₩425.1B	₩200.9B	₩140.9B	47.2%	14.8%	9.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

On an annual basis, revenue and operating profit expanded for three consecutive years, from 281.7 billion won and 101.4 billion won in 2022 to 319.7 billion and 117.8 billion in 2023, 373.0 billion and 166.2 billion in 2024, and 425.1 billion and 200.9 billion in 2025.

Operating margin rose over the same span from 36.0 percent in 2022 to 36.8 percent in 2023, 44.6 percent in 2024 and 47.2 percent in 2025, while 2025 net profit attributable to owners was 140.9 billion won and operating cash flow was 150.1 billion won.

The balance sheet is light, with total liabilities of 96.7 billion won against equity of 980.2 billion won, a debt-to-equity ratio near 9.9 percent.

Quarterly revenue moved from 110.3 billion won in the second quarter of 2025 to 105.9 billion, 119.1 billion, 116.6 billion and 137.9 billion won through the second quarter of 2026.

Operating profit, by contrast, went from 56.7 billion won in the second quarter of 2025 to 47.6 billion in the first quarter of 2026 and 56.0 billion in the second, with the margin easing from roughly 51 percent to about 41 percent.

In other words, the second quarter of 2026 paired the highest revenue with the lowest margin of the past five quarters, which the company explained as the effect of upfront investment in the US direct-sales structure and strategic marketing.

Reports that second-quarter selling and administrative expenses rose 66 percent year on year to 49.7 billion won point in the same direction.

On earnings quality, net profit attributable to owners hit a quarterly high of 43.3 billion won in the second quarter of 2026, and 2025 operating cash flow did not lag operating profit by a wide margin.

Industry analysis

Botulinum toxin demand, rooted in aesthetic procedures, has spread from the United States and Europe into Asia and Latin America, and Korean producers' export share has been rising quickly.

One market study projected the US toxin market growing from 4.74 billion dollars in 2023 to 6.68 billion dollars by 2030, while another research house expected China's market to expand from 12.6 billion yuan in 2025 to 39.0 billion yuan by 2030.

Korea is described as a market where more than fifteen products compete, and Hugel leans on Letybo, sold domestically as Botulax, having ranked first in domestic unit sales for ten consecutive years.

Domestic maturity and competition also show in the numbers: combined domestic toxin and filler sales grew only 2.5 percent in the first half of 2026.

On the competitive map, Daewoong Pharmaceutical's Nabota is sold in the United States as Jeuveau through partner Evolus, which reported a 14 percent share of the US aesthetic toxin market in 2025, whereas Letybo has been described as holding around 3 percent in its early launch phase.

Hugel therefore has to build share against large global incumbents and an earlier-moving Korean rival.

Separately, the company previously received a final determination in a US International Trade Commission proceeding brought by Medytox finding no violation regarding strain and related issues, so the industry-specific strain dispute variable is regarded as settled for now.

Outlook

The clearest confirmed change is the US sales structure. The company held a national sales meeting in Los Angeles on July 8, 2026 to start direct sales of Letybo, targeting roughly eighty med spas and clinics that do not overlap with BENEV's distribution network.

Analysts have noted that because the average selling price in US direct channels is three to five times the domestic level and the distributor margin is captured internally, the impact shows up more in profitability than in revenue.

Management has stated targets of a 5 percent US toxin share in 2026, 10 percent in 2028 and 14 percent in 2030, with a direct-sales organization of 100 to 120 people by 2028, alongside a goal of 900 billion won in US revenue in 2028 and an overseas revenue share of 75 percent.

On costs, the company indicated that spending on non-commercial validation batches at the third plant and on the direct-sales build-out began flowing through from the second quarter, and Hana Securities analyst Kim Da-hye said in July 2026 that the second quarter would mark the year's lowest operating margin.

On products, an extracellular matrix skin booster has launched domestically, and the US entity is reported to be aiming for two skincare launches in 2027. Under the current distribution agreement, the Letybo supply contract with BENEV runs to July 2027, leaving the question of a full shift to direct sales open.

These figures are company plans, however, and the actual pace of share gains, pricing and cost recovery is still being verified quarter by quarter.

Valuation

PER

16.6×

PBR

2.5×

ROE

16.5%

EPS

₩14,669

BPS

₩97,671

Dividend per share

₩0

Hugel's earnings multiple is calculated on the most recent four quarters of results, a window (third quarter 2025 through second quarter 2026) that already embeds two quarters of US direct-sales costs.

Relative to book value the shares trade at a premium to net assets, and it is worth noting that the same share price yields a different book multiple depending on whether the company's own per-share net asset figure or the Korea Exchange basis is used.

No cash dividend per share is confirmed in disclosures, so dividends currently contribute essentially nothing to total shareholder return. As for brokerage views, NH Investment & Securities was reported in a May 2026 note to have maintained a buy rating and raised its target price from 350,000 won to 400,000 won.

That is the brokerage's view and not KOSAI's judgment. Ultimately, how the multiple is read depends on how much of the elevated selling and administrative spending from the direct-sales transition is recovered through higher pricing and share gains, and the check point for that is the upcoming quarterly results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Accelerating Overseas Toxin Growth

First-half 2026 toxin revenue rose 46.6 percent year on year to 149.4 billion won, driving company-wide growth.

Overseas toxin and filler sales of 162.1 billion won made up roughly 64 percent of total revenue, and sales in the Americas, including the United States and Brazil, were reported to have more than doubled year on year.

Asia Pacific and Europe also grew in the mid-to-high twenties in percentage terms, so growth was not concentrated in a single region. This is consistent with the export share rising from 53.3 percent in 2023 to 63.2 percent in 2025 per company filings.

Pricing Structure Shift From Direct Sales

Hugel began US direct sales on July 8, 2026, moving to a hybrid structure that combines partner distribution with its own selling.

Industry analysis argues the impact will be larger on profitability than revenue, since US direct-channel average selling prices are three to five times domestic levels and the distributor margin is captured internally.

The initial focus is roughly eighty strategic accounts that do not overlap with BENEV's network, limiting channel conflict. This represents room for margin improvement as a business metric, and actual delivery must be confirmed in quarterly results.

Near Debt-Free Balance Sheet and Cash Generation

At the end of 2025, consolidated liabilities were 96.7 billion won against equity of 980.2 billion won, a debt-to-equity ratio of about 9.9 percent. Operating cash flow of 150.1 billion won in 2025 was not far below operating profit of 200.9 billion won, following 149.1 billion won in 2024.

That financial headroom reduces reliance on outside funding during a phase that requires upfront spending, such as building a US sales force and adding new products. Even so, there remains a lag before such investment converts into revenue.

Bear factors

Margin Decline and Cost Persistence

Second-quarter 2026 operating profit of 56.0 billion won was slightly below the 56.7 billion won a year earlier, and the operating margin fell from about 51 percent in the second quarter of 2025 to roughly 41 percent.

Second-quarter selling and administrative expenses were reported at 49.7 billion won, up 66 percent year on year, and with the direct-sales team set to expand to 100 to 120 people by 2028, much of the personnel and marketing cost is structural.

The company and brokerages have projected margin improvement from the third quarter, but whether the cost recognition truly ends as a one-off has not yet been confirmed in results. If cost growth outpaces price and volume effects, the gap between revenue growth and profit growth could persist.

Slow Domestic Growth and Intensifying Competition

Combined domestic toxin and filler sales in the first half of 2026 rose only 2.5 percent to 53.5 billion won. Korea is described as a market where more than fifteen products compete, and the company says it is responding with bundling and portfolio diversification.

With industry commentary noting that the domestic aesthetics market has entered a mature phase with limited growth room, the weight of growth is shifting further overseas. If overseas progress is slower than expected, the domestic business would be ill-placed to cushion it.

Gap Between US Share Targets and Reality

Management targets a US share of 5 percent in 2026, 10 percent in 2028 and 14 percent in 2030, but the early-launch share has been described as around 3 percent.

By contrast, Jeuveau, the US brand for Daewoong Pharmaceutical's Nabota, held a 14 percent share of the US aesthetic toxin market in 2025 according to its partner. The US market is characterized as led by a small number of large global players, and a late entrant must absorb continuing sales-force and marketing costs.

How fast the gap between targets and actual share narrows may be the central point of debate for future results.

Risk factors

Ownership and Overhang

Aphrodite Acquisition Holdings and related parties held 45.58 percent as of August 4, 2026, and disclosures show share pledge agreements tied to loans of 675.0 billion won and 90.0 billion won.

Reports about stake-sale reviews by consortium members such as CBC Group and about a recapitalization have surfaced repeatedly since 2025, with company and market comments generally cautious at each stage.

A private-equity-centered ownership structure carries recurring non-operational variables such as control changes, large block transfers and listing-related rumors. Investors should track the ownership disclosures themselves as discrete facts.

Regulation and Litigation

Botulinum toxin is an industry with a history of disputes over strain origin and cross-border export procedures, and Hugel itself received a final determination of no violation on strain-related issues after a US International Trade Commission proceeding brought by Medytox.

Even so, maintaining approvals, hosting site inspections and obtaining new indications and product clearances across US, Chinese and European regimes each require separate processes and time.

There are also periods in which regulatory work itself is expensed, such as non-commercial validation batch production at the third plant. Delays in regulatory timelines can directly affect when revenue is recognized and how quickly costs are recovered.

Overseas Dependence and Channel Transition

The overseas revenue share reached 67 percent in the second quarter of 2026 and management aims to lift it to 75 percent by 2028, which increases exposure to currency moves, local consumer conditions and distribution partners.

The Letybo supply contract with BENEV runs to July 2027, and reports indicate minimum volumes will be allocated to BENEV from the third quarter, so revenue recognition and inventory flows could change as the channel is reorganized around the contract's end.

In a structure that runs direct and indirect sales in parallel, friction over pricing and account allocation between channels cannot be ruled out. The distribution strategy for the planned US skincare products has also not yet been detailed.

What to watch next

Early November 2026
Third-quarter 2026 results. This is the first full quarter after direct sales began on July 8, so the key check is whether growth in selling and administrative expenses slows enough for the operating margin to rebound from the 40 percent range seen in the first and second quarters of 2026.
Fourth quarter of 2026
Progress against the company's stated 2026 US share target of 5 percent and the pace of direct-channel expansion. Watch for expansion beyond the roughly eighty strategic accounts and any change in how minimum volumes are allocated to BENEV.
Around February 2027
Full-year 2026 results disclosure. It will show whether the first-half revenue pace of 254.5 billion won continued, where the annual operating margin settled relative to 47.2 percent in 2025, and whether dividend policy changes.
First half of 2027
Preparations for the two skincare launches the US entity has targeted, and confirmation of their distribution channels. This will help gauge whether the direct-sales organization is being leveraged to improve the investment efficiency of the US business.
July 2027
Expiry of the Letybo supply agreement with BENEV. Whether the company discloses a full shift to direct sales, a contract extension or a continued hybrid model will change the structure of US revenue recognition and margin composition.

Overall view

Hugel has a track record of expanding revenue from 281.7 billion won in 2022 to 425.1 billion won in 2025 and operating profit from 101.4 billion won to 200.9 billion won, lifting its operating margin from the 36 percent area to 47.2 percent.

Into 2026 top-line growth actually accelerated, with second-quarter revenue of 137.9 billion won setting a quarterly record, yet operating profit of 56.0 billion won in that quarter came in below the 56.7 billion won of a year earlier and the margin slipped into the 40 percent range.

The company attributes the gap to upfront investment in the US direct-sales structure and marketing, supported by reports that second-quarter selling and administrative expenses rose 66 percent.

The bullish case rests on rapid growth in overseas toxin sales, the pricing structure change from the direct-sales shift, and balance-sheet capacity with a debt-to-equity ratio under 10 percent.

The bearish case rests on domestic stagnation visible in the 2.5 percent growth of domestic toxin and filler sales, the distance between targets such as a 10 percent US share in 2028 and the current early-stage share, and the structural nature of sales and marketing costs.

Ownership issues that recur around a private-equity consortium holding 45.58 percent remain a non-operational variable. The next checkpoint is therefore clear: whether the increased spending is recovered through pricing and share in the upcoming third-quarter and full-year results. This report is for information purposes and contains no buy or sell opinion and no target price.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.